Navigation Links
AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting

nificant and clinically meaningful efficacy in the treatment of LUTS secondary to BPH; - No statistically significant impact on quality of life or erectile function; and - Intramuscular 15 mg + 15 mg was the most effective regimen in this study. About Ozarelix and Partnerships

Ozarelix is a fourth generation luteinizing hormone-releasing hormone (LHRH) antagonist administered as a depot formulation for the treatment of benign and malign hormone-dependent diseases. It is currently in Phase 2b clinical trials for both BPH and prostate cancer.

In August 2004, AEterna Zentaris granted Spectrum Pharmaceuticals an exclusive license to develop and market ozarelix for all potential indications in North America and India, while AEterna Zentaris retains exclusive rights to the rest of the world. Spectrum will also receive 50% of any upfront and milestone payments, royalties and/or profits from sales of the product in Japan.

Furthermore, AEterna Zentaris recently granted Japanese rights for all potential oncology indications to Nippon Kayaku, a key player in the Japanese oncology market.

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate frequently occurring in men over the age of 50. The enlargement can result in the gradual squeezing of the urethra, resulting in increased frequency or difficulty in urinating. Enlargement of the prostate is controlled by testosterone. According to the National Institutes of Health, BPH affects more than 50% of men over the age of 60 and as many as 90% of men over the age of 70. Treatment options for BPH include surgery and medications to reduce the amount of tissue and increase the flow of urine. Current treatment options are inconvenient, leading to ineffective compliance and are only effective in roughly half of the patients treated. According to Decision Resource, in 2004, the total prevalence cases
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/29/2014)... 2014   Mast Therapeutics, Inc. (NYSE ... that Santosh Vetticaden, Chief Medical Officer and Senior ... personal reasons, in mid-September.  Edwin L. Parsley ... Pharmaceuticals, which Mast acquired earlier this year, will ... interim Chief Medical Officer.  Dr. Parsley previously was ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... 19, 2012 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: ... product line has experienced double digit sales growth in ... is expected to generate an estimated 50 million yuan ... strength of the Company,s core product lines and rapid ...
... --  Terumo Cardiovascular Systems announced today that it has ... distribute the TigerPaw® System II, a left atrial appendage ... TigerPaw System II is indicated for occlusion of the ... other open cardiac procedures.  It is new to the ...
Cached Medicine Technology:China Health Resource Pharmaceutical Grade Gastrodia Product Line Expected to Contribute $8 Million in Revenue to 2011 Year End 2China Health Resource Pharmaceutical Grade Gastrodia Product Line Expected to Contribute $8 Million in Revenue to 2011 Year End 3Terumo Cardiovascular Systems Becomes Exclusive U.S. Distributor for TigerPaw® System II, Left Atrial Appendage Closure Device 2
(Date:8/30/2014)... 2014 United Theological Seminary is pleased to ... the Master of Theological Studies (MTS). , ... designed for students who wish to pursue further academic study ... to serve the Church and community. Previously, students needed to ... can attend classes from any location where there is an ...
(Date:8/30/2014)... Daily Gossip reveals in its recently published review ... created by Sarah Summer, who can perfectly understand what suffering ... new program actually had to deal with this disorder, too. ... to access it, in an all-natural holistic cure program. , ... effective cure for yeast infection. The author of this program ...
(Date:8/30/2014)... 30, 2014 The establishment and ... has been one of the main strategies of ... a positive impact around the world. , Architecturally ... top trained executives and trainers deliver L. Ron ... Vital statistics demonstrate that significant reduction in ...
(Date:8/30/2014)... New York, New York (PRWEB) August 30, 2014 ... and other incretin mimetic claims continue to move forward ... a statement issued by AstraZeneca PLC on July 31, ... have been named in 409 product liability claims that ... cancer. Court documents indicate that many of these claims ...
(Date:8/30/2014)... 30, 2014 Hastings and Hastings, a ... located throughout Arizona is pleased to report having saved ... specific example among many cases where Hastings and Hastings ... to retain a greater portion of their settlement or ... providing a positive solution for Arizona car accident victims ...
Breaking Medicine News(10 mins):Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2
... lags behind in curbing the maternal and infant mortality ... childbirth complications. ,"Maternal health is the foundation ... function organised here Monday on the eve of Safe ... several MPs and Delhi Health Minister Yoganand Shastri, Hota ...
... due at least in part to an attraction between ... stop eating, and a protein more recently// associated with ... not only binds to leptin but its hold impairs ... may help explain why obese people have so much ...
... Sunday saw yet another nationwide polio immunization drive. However, ... upon officers in Western Uttar Pradesh// whose laxity he ... ,Several officers have been punished in this ... officers according to the Health Minister. ...
... revealed that infants of habitually snoring parents are also ... addition researchers have also found that children with atopy ... snoring. ,Sleep-disordered breathing among children had been ... disorders and heart disease. ,When airflow becomes ...
... requiring work permit to be made mandatory for non-European doctors, ... Service// (NHS), has brought about nervousness among the Indian doctors. ... doctors already working there are expected to be affected in ... assignment. With this rule it would become almost impossible for ...
... Jude Children's Research Hospital in Memphis have found that ... in their parents and vice versa.// Their study, which ... a peer-reviewed journal of the American Cancer Society, says ... health related quality of life (HRQL) as their kid. ...
Cached Medicine News:Health News:Maternal Mortality Rate On Rise In India 2Health News:Researchers Identify The Cause To Obesity 2Health News:Researchers Identify The Cause To Obesity 3Health News:Snoring Runs in the Family 2
... Akers, our ultimate goal is to provide ... and immediate treatment. Each year millions of ... die from late detection or undetected disease ... cripple nations., ,By developing, manufacturing and marketing ...
... BD Macro-Vue RPR (Rapid Plasma Reagin) ... Tests are nontreponemal testing procedures for ... in A Manual of Tests for ... manual are the most widely used ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
... assurance reagent in assays detecting IgG and IgM ... IgM), IgG and IgM antibodies to rubella virus ... antibodies to cytomegalovirus (CMV IgG and IgM), and ... types 1 and 2 (HSV-1 IgG, HSV-1 IgM, ...
Medicine Products: